Cencora, Inc. (COR) — Q3 FY2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into COR's Q3 FY2026 print is modestly constructive — consensus EPS of ~$4.35–$4.37 implies high-single-digit growth in line with management's own Q3 cadence guide, leaving the bar achievable, but the biggest swing factor is whether the biosimilar conversion headwind at the large mail-order customer has stabilized or continues to accelerate beyond what was already baked into the May guidance cut.

Heading into the Q3 print, the bar is calibrated rather than stretched: management explicitly guided Q3 adjusted diluted EPS growth to be in the high single digits, and consensus at ~$4.35–$4.37 sits squarely in that range, leaving little room for a dramatic upside surprise but also limiting downside risk if execution is clean. The tone from the May 6 earnings call was one of confident resilience — management characterized Q2 headwinds (weather, COVID vaccine comp, biosimilar conversions) as transitory and reiterated full-year U.S. Healthcare Solutions operating income growth guidance of 14%–16%, with the strongest quarter expected in Q4 after lapping the oncology customer loss. Estimate revisions have been modestly positive since the Q2 print, with the 30-day EPS revision trend up ~1.3%, suggesting the Street has largely digested the revenue guide cut and is now focused on operating income durability. The stock has recovered sharply from its post-Q2 lows — up ~21% from the May 6 close of $252.74 to ~$306 as of August 4 — outperforming both XLV (+11.5%) and the S&P 500 (+5.1%), implying the market has already priced in a clean quarter and is looking for confirmation of the Q4 acceleration thesis. The key wildcard is the pace of Part D biosimilar conversions at the large mail-order pharmacy customer: if the conversion rate has moderated as management implied, revenue and operating income should track guidance; if it has accelerated further, another revenue guide cut — even if low-margin — could rattle sentiment again.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a calibrated, achievable bar — adjusted EPS of ~$4.35–$4.37 aligns with management's own high-single-digit Q3 growth guide; the bigger swing factor is

Key Takeaway: Consensus is a calibrated, achievable bar — adjusted EPS of ~$4.35–$4.37 aligns with management's own high-single-digit Q3 growth guide; the bigger swing factor is U.S. Healthcare Solutions operating income, where the Street expects ~$940M, implying ~4% YoY growth as the oncology customer lap and OneOncology ramp begin to offset headwinds.

Key Takeaway: Consensus is a

Key Takeaway: Consensus is a calibrated, achievable bar — EPS at ~$4.35–$4.37 aligns with management's own high-single-digit Q3 growth guide, making

Key Takeaway: Consensus is a calibrated, achievable bar aligned with management's own high-single-digit Q3 EPS growth guide; the bigger swing factor is

Table 1 — Current Quarter Snapshot (Q3 FY2026)

Sources: Visible Alpha Consensus and Actuals Data. Q3 FY26 consensus as of August 4, 2026. Q2 FY26 actuals and Q3 FY25 actuals from Visible Alpha. Guidance from COR Q2 FY2026 earnings call (May 6, 2026).

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Top KPI 1: Adjusted Diluted EPS

Pattern: COR has beaten adjusted EPS consensus in 7 of the last 8 quarters, with an average beat of ~3.6%; the lone miss was Q2 FY2026 (-1.0%), driven by faster-than-expected biosimilar conversions and slower GLP-1 growth — both of which management characterized as transitory. Source: Visible Alpha Consensus and Actuals Data.

Top KPI 2: U.S. Healthcare Solutions Operating Income

Pattern: U.S. Healthcare Solutions operating income has been a more volatile KPI, missing consensus in 6 of the last 8 quarters as the Street has repeatedly overestimated the segment; the two beats (Q2 FY25, Q1 FY26) coincided with strong specialty volumes. Consensus at $940M for Q3 FY26 implies ~+13% YoY growth, which is achievable given the partial oncology customer lap and OneOncology ramp. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has not been formally revised since the May 6 Q2 earnings call; the only post-earnings development was the March 17 CFO retirement announcement (which included a reaffirmation of FY26 EPS guidance), and the June 15 appointment of a new CHRO. Management tone remains

Key Takeaway: No formal guidance revision since the May 6 Q2 earnings call; management tone remains

Key Takeaway: No formal guidance revision since the May 6 Q2 earnings call; management tone remains confident on operating income durability despite the revenue guide cut, with the Q4 acceleration thesis (oncology customer lap + OneOncology ramp) intact.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been largely stable-to-modestly-higher since the Q2 print, with the 30-day EPS revision trend up ~1.3%; the Street has absorbed the revenue guide cut and is now focused on operating income, where consensus tracks the midpoint of management's guidance range — suggesting no meaningful gap risk on the profit line heading into Q3.

Estimates have been remarkably stable since the Q2 print, with virtually no revision in either direction — the Street has accepted management's framing that the revenue headwinds are low-margin and therefore not meaningful to operating income. The slight downward drift in U.S. HCS operating income estimates (-0.6% for Q3) suggests modest caution on the segment, but the gap vs. guidance is not alarming. Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: COR has dramatically outperformed both XLV and the S&P 500 since the Q2 print — up ~21% vs. +11.5% for XLV and +5.1% for SPY — driven by

Key Takeaway: COR has dramatically outperformed both XLV (+11.5%) and the S&P 500 (+5.1%) since the Q2 print, recovering all of its post-earnings losses and then some; the re-rating appears driven by multiple expansion and renewed confidence in the operating income durability thesis rather than estimate revisions, which have been flat.

COR vs. XLV vs. S&P 500 — Indexed to 100 at May 6, 2026 (Q2 FY2026 Earnings Date). Source: Stock Price Data.

• May 6, 2026 (Q2 Earnings): COR fell from $305.90 (May 5 close) to $252.74 on earnings day — a decline of ~$53 / -17.4% — as the revenue guidance cut from +7%–9% to +4%–6% shocked the Street despite the EPS guidance raise.
• May 6 – June 15: Gradual recovery from the post-earnings lows as investors digested management's message that revenue headwinds are low-margin and operating income guidance is intact. Stock climbed from $252.74 to ~$281 (+11%).
• June 15, 2026: Cencora named Verizon veteran Hammock as new HR Chief (8-K). Stock reaction was muted; the appointment signals continued organizational build-out.
• July 1–August 4: Strong rally from ~$282 to ~$320 peak (July 28) before modest pullback to $306 as of August 4. The rally coincided with broader healthcare sector strength (XLV +11.5% over the same period) and growing conviction in the Q4 acceleration thesis.
• As of August 4, 2026: COR at $306.28, indexed at 121.2 vs. XLV at 111.5 and SPY at 105.1 (base = 100 at May 6 close). The stock's outperformance suggests the market has priced in a clean Q3 print and is looking for Q4 guidance confirmation.

6. Peer Commentaries — Read-Through for COR Q3 FY2026

Key Takeaway: Peer commentary from McKesson (Q4 FY2026 earnings, May 7, 2026) and Cardinal Health (Q3 FY2026 earnings, April 30, 2026) provides the most relevant forward-looking read-through for COR's April–June 2026 quarter, confirming

Key Takeaway: Peer commentary from McKesson (reported May 7) and Cardinal Health (reported April 30) provides the most relevant forward-looking read-through for COR's Q3 FY2026 (Apr–Jun 2026): both peers confirm

Key Takeaway: McKesson and Cardinal Health commentary from their most recent earnings calls (both covering the April–June 2026 period in their forward guidance) confirms continued specialty pharma strength, manageable IRA/biosimilar dynamics, and robust oncology demand — all constructive read-throughs for COR's Q3 print. Henry Schein's Q2 2026 results (reported August 4) add a real-time data point on stable healthcare market conditions.

Note on peer selection: Only forward-looking commentary about the April–June 2026 calendar period is included below. Commentary about peers' own historical quarter results has been excluded. MCK's Q4 FY2026 call (May 7, 2026) and CAH's Q3 FY2026 call (April 30, 2026) both provided explicit FY2027/Q4 FY2026 outlooks covering the April–June 2026 window. HSIC's Q2 2026 call (August 4, 2026) provides same-day market color.

McKesson (MCK) — Q4 FY2026 Earnings Call, May 7, 2026

Relevance: MCK's FY2027 guidance (issued May 7) covers the April–September 2026 period, directly overlapping with COR's Q3 FY2026. MCK is COR's closest peer in pharmaceutical distribution.

• Specialty Pharma Strength (Constructive → COR): "Specialty continues to be where you're seeing the most innovation. You're seeing the most growth of all categories." MCK guided North American Pharma segment operating profit growth of +5.5% to +9.5% for FY2027, supported by "stable prescription volume growth." This confirms the specialty distribution tailwind that underpins COR's U.S. HCS operating income growth thesis.
• GLP-1 Dynamics (Mixed → COR): GLP-1 distribution revenues reached $14B in MCK's Q4 FY2026, up 22% YoY but down 4% sequentially. MCK noted "no impact" on operating profit from the sequential decline, consistent with COR's characterization of GLP-1 as low-margin revenue. MCK guided "continued category growth in fiscal 2027 with quarter-to-quarter variability" — suggesting GLP-1 growth moderation is a sector-wide dynamic, not COR-specific.
• Biosimilar Conversions (Constructive for Part B, Neutral for Part D → COR): MCK described biosimilars as a "win-win-win" and highlighted the community Part B channel as "most attractive." MCK noted 89 approved biosimilars and 72 launched, with network effects in U.S. Oncology enabling rapid adoption. This supports COR's thesis that Part B biosimilar conversions are incrementally beneficial, while Part D conversions (the headwind) are a revenue-only impact.
• IRA/Drug Pricing (Manageable → COR): MCK "successfully navigated the first wave of branded pharmaceutical price changes related to the IRA," noting revenue impact but "double-digit adjusted segment operating profit growth in fiscal 2026." IRA WAC changes reduced MCK's Q4 revenue growth by ~3% — consistent with the ~$2B revenue headwind COR cited in Q2. Both companies confirm the impact is revenue-concentrated, not profit-concentrated.
• Oncology Platform Expansion (Constructive → COR): MCK's U.S. Oncology Network added 570+ providers in FY2026 (largest net increase since 2010) and expanded with Cancer Care Northwest in April 2026. PRISM Vision (retina/ophthalmology) grew providers ~20% YoY. MCK guided oncology/multispecialty segment operating profit growth of +13.5% to +17.5% for FY2027. This validates the oncology MSO growth thesis that COR is pursuing through OneOncology and RCA.
• Health System Trends (Constructive → COR): MCK noted "good growth" in specialty products within health systems, with a "strong value proposition." This aligns with COR's Accelerate Pharmacy Solutions portfolio targeting health system specialty needs.

Cardinal Health (CAH) — Q3 FY2026 Earnings Call, April 30, 2026

Relevance: CAH's Q3 FY2026 call (January–March 2026 results) included explicit forward guidance for Q4 FY2026 (April–June 2026) and FY2027, directly covering COR's Q3 FY2026 period. CAH is onboarding new distribution volumes (GI Alliance, Solaris) in Q4 FY2026, providing a real-time read on pharma distribution demand.

• Specialty Pharma Demand (Constructive → COR): CAH's Specialty revenue grew over 20% in Q3 FY2026 (consistent with prior two quarters) and is expected to exceed $50B for FY2026. CAH guided "positive demand and demographic trends to persist" in Pharma & Specialty for FY2027. The multi-specialty MSO strategy (Specialty Alliance) is described as a "key differentiator" — directly analogous to COR's OneOncology/RCA platform.
• GLP-1 Dynamics (Consistent with COR's Framing → COR): GLP-1s contributed 6 percentage points to CAH's revenue growth in Q3 FY2026, but growth moderated from the prior quarter. CAH characterized GLP-1s as "relatively empty calorie dollars" — high revenue, low profit — exactly mirroring COR's characterization. This confirms that GLP-1 growth moderation is a sector-wide dynamic with minimal profit impact.
• IRA/WAC Pricing Impact (Manageable → COR): IRA WAC pricing adjustments had a 6 percentage point impact to CAH's Q3 revenue, "generally offsetting" GLP-1 growth. CAH stated it "maintained its economics on distribution contracts" and renegotiated contracts at the beginning of Q3 FY2026. CAH expressed "high confidence" that fees for services should not change. This is a strong read-through that COR's distribution economics are similarly protected.
• Biosimilar/Generic Conversions (Profit-Positive → COR): CAH noted that loss-of-exclusivity (LOE) to generics is a "downdraft on revenue, but a positive for us from a profit perspective." This is consistent with COR's messaging that biosimilar conversions in the Part B channel are incrementally beneficial to profitability.
• Oncology MSO — Navista Impairment (Nuanced → COR): CAH recorded a $184M goodwill impairment on its Navista oncology MSO business, attributed to a market shift toward equity arrangements with physicians over non-equity models. Importantly, CAH stated this does not alter the broader MSO strategy and the impairment is non-cash/non-GAAP. The read-through for COR is nuanced: the market is validating equity-based MSO models (which COR pursues through OneOncology), but also signals that non-equity MSO models face headwinds.
• Pharmaceutical Distribution Volumes (Constructive → COR): CAH's Pharma segment revenue grew 11% to $56.1B in Q3 FY2026, driven by "existing customer growth across the portfolio." CAH is onboarding GI Alliance and Solaris distribution volumes in Q4 FY2026 (April–June 2026), indicating robust new business activity in the distribution channel. Brand volume growth described as "healthy."

Henry Schein (HSIC) — Q2 2026 Earnings Call, August 4, 2026 (Same-Day)

Relevance: HSIC reported Q2 2026 results (April–June 2026) on August 4, 2026 — the same day as this preview. While HSIC's core business (dental/non-acute medical supplies) is less directly comparable to COR's pharmaceutical distribution, its commentary on healthcare market conditions and physician practice trends provides same-day market color.

• Healthcare Market Conditions (Constructive → COR): HSIC described its markets as "stable and durable" with "good underlying fundamentals and a long runway for growth." The company is "not seeing a significant impact on patient volumes resulting from higher oil prices" and believes markets are "resilient to economic pressure." Patient traffic "remained stable throughout the quarter." This broad market stability is a constructive backdrop for COR's physician practice and health system volumes.
• Non-Acute Care Demand (Constructive → COR): HSIC noted the non-acute care U.S. medical market "remains solid," with Home Solutions growing in the "high single digits" approaching double digits. Procedures continue to shift to non-acute settings. This secular shift supports COR's specialty distribution to physician practices and ambulatory settings.
• Specialty Products (Constructive → COR): HSIC's Global Specialty Products Group grew 8.7% overall, with specialty markets described as having "healthy underlying fundamentals." European specialty volumes noted as ahead of the U.S. This is consistent with COR's International Healthcare Solutions segment benefiting from European distribution strength.
• Physician Practice Trends (Constructive → COR): HSIC noted DSOs are "continuing to invest in equipment" and gaining market share. Practice efficiency and workflow optimization are key themes. HSIC expects "earnings growth in the fourth quarter to exceed that in the third quarter" — suggesting sequential improvement in healthcare market activity, which would benefit COR's Q4 FY2026 (the quarter management has flagged as the strongest of the year).
• Diagnostic Products Headwind (Limited Read-Through → COR): HSIC noted "continued headwinds in point-of-care diagnostic product sales" in Q2, but characterized this as "less significant in the middle of the year" (Q2/Q3) vs. Q4/Q1 respiratory season. This is a HSIC-specific dynamic with limited read-through to COR's pharmaceutical distribution business.

Overall Peer Read-Through Summary: The peer commentary is broadly constructive for COR's Q3 FY2026 print. MCK and CAH both confirm that (1) specialty pharma demand remains robust, (2) IRA/WAC pricing impacts are revenue-concentrated and manageable, (3) GLP-1 growth moderation is sector-wide and profit-neutral, and (4) oncology MSO platforms continue to expand. The CAH Navista impairment is a nuanced data point but validates COR's equity-based MSO model. HSIC's same-day commentary confirms stable healthcare market conditions heading into the print.

7. Material News & Developments

Key Takeaway: The most important post-Q2 development is the appointment of a new CFO (Eva Boratto, effective June 2026), which brings leadership continuity risk but also signals a clean transition; the EyeSouth Partners retina acquisition (announced March 2026, expected to close after fiscal year-end) is the key strategic catalyst not yet in guidance.

• June 30, 2026 — New CFO Eva Boratto Receives RSU Grant: Eva Boratto (new CFO, replacing retiring Jim Cleary) received 21,304 RSUs on June 29, 2026, signaling her formal onboarding. Cleary's retirement was announced March 17 alongside a reaffirmation of FY26 EPS guidance. Boratto's appointment is a key leadership transition to monitor; her first earnings call will be Q3 FY2026 (August 5).
• June 15, 2026 — New CHRO Appointed (Verizon Veteran Hammock): Cencora named a new Chief Human Resources Officer from Verizon, signaling continued organizational build-out as the company integrates OneOncology and RCA. Limited direct financial impact but reflects management's focus on talent infrastructure for the MSO platform.
• May 6, 2026 — Q2 FY2026 Earnings: Revenue Guide Cut, EPS Guide Raised: Full-year revenue growth guidance cut from +7%–9% to +4%–6% due to faster-than-expected biosimilar conversions at large mail-order customer and slower GLP-1 growth. FY26 adjusted EPS guidance raised to $17.65–$17.90 (from $17.45–$17.75), partly reflecting MWI held-for-sale depreciation suspension. Share repurchases resumed, targeting $1B by calendar year-end. CFO Jim Cleary's final earnings call.
• April 30, 2026 — U.S. Hub Consulting Services Divested: Cencora completed the divestiture of its U.S. hub consulting services business, sharpening focus on the pharmaceutical-centric strategy. This was a headwind to International Healthcare Solutions revenue but removes a non-core business. Implication: cleaner segment reporting going forward.
• March 23, 2026 — EyeSouth Partners Retina Acquisition Announced: Cencora announced the acquisition of EyeSouth Partners' retina business, expected to close after fiscal year-end (post-September 2026). Not included in FY26 guidance. This is a significant strategic expansion into the retina MSO space, complementing the oncology MSO platform. Implication: potential upside catalyst for FY27 guidance when the deal closes.
• March 17, 2026 — CFO Jim Cleary Retirement Announced; FY26 EPS Guidance Reaffirmed: Cencora announced CFO Jim Cleary's retirement (effective June 2026, departing December 2026) alongside a reaffirmation of FY26 adjusted EPS guidance. The reaffirmation was a positive signal that the CFO transition is not disrupting financial execution.
• February 18, 2026 — MWI Animal Health / Covetrus Merger Announced ($3.5B): Cencora announced the merger of MWI Animal Health with Covetrus in a $3.5B deal, expected to close in FY2027. MWI classified as held-for-sale, suspending depreciation and boosting the "Other" segment's operating income. Implication: ~$50–60M annual depreciation benefit to operating income in FY26 from held-for-sale accounting.
• February 4, 2026 — OneOncology Acquisition Completed ($4.6B): Cencora completed the acquisition of a majority stake in OneOncology for $4.6B, funded by $3B senior notes (priced February 2026) and term loans. OneOncology is now being integrated with RCA under a unified MSO platform. Implication: accretion expected to ramp through FY26, with the strongest contribution in Q4 after lapping the oncology customer loss.

8. Insider Transaction Activity

Key Takeaway: The most notable signal is

Key Takeaway: The most notable signal is two open-market purchases by Director Dermot Durcan (8,000 shares total, ~$2.1M, in May–June 2026) at prices well below current levels — a constructive signal from a board member buying into post-earnings weakness. No open-market sales by insiders in the period.

Analysis: The insider picture is constructive. Director Dermot Durcan made two consecutive open-market purchases totaling 8,000 shares (~$2.1M at estimated prices of ~$260–$272) in May–June 2026, buying directly into post-earnings weakness — a meaningful signal of board-level conviction. Director Lauren Tyler also made a small open-market purchase in June. There are no open-market sales in the period. The CFO RSU grant to Eva Boratto is a routine onboarding award, not a market signal. All other transactions are compensation awards (Form 4 code A). Source: Insider Transaction Data (SEC Form 4).